- Home
- M vs TVTX Comparison
M vs TVTX Comparison
Compare M & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | TVTX |
|---|---|---|
| Founded | 1830 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.3B |
| IPO Year | 2003 | 2013 |
Fundamental Metrics
Financial Performance| Metric | M | TVTX |
|---|---|---|
| Price | $23.08 | $65.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $20.09 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | 12.08 | ★ 92.89 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $22,621,000,000.00 | N/A |
| Revenue This Year | N/A | $44.76 |
| Revenue Next Year | N/A | $35.51 |
| P/E Ratio | $97.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.41 | $22.06 |
| 52 Week High | $26.59 | $68.03 |
Technical Indicators
Market Signals| Indicator | M | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 60.45 |
| Support Level | $22.06 | $53.76 |
| Resistance Level | $22.92 | $66.24 |
| Average True Range (ATR) | 0.62 | 1.98 |
| MACD | -0.10 | -0.14 |
| Stochastic Oscillator | 31.85 | 71.85 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.